Regeneron Pharmaceuticals Inc (REGN)
902.03
+7.89
(+0.88%)
USD |
NASDAQ |
Apr 17, 16:00
902.03
0.00 (0.00%)
After-Hours: 17:40
Regeneron Pharmaceuticals SG&A Expense (Quarterly): 737.70M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 737.70M |
September 30, 2023 | 640.50M |
June 30, 2023 | 652.00M |
March 31, 2023 | 601.10M |
December 31, 2022 | 660.50M |
September 30, 2022 | 529.10M |
June 30, 2022 | 476.30M |
March 31, 2022 | 450.00M |
December 31, 2021 | 559.60M |
September 30, 2021 | 445.00M |
June 30, 2021 | 414.70M |
March 31, 2021 | 405.60M |
December 31, 2020 | 303.50M |
September 30, 2020 | 326.90M |
June 30, 2020 | 348.30M |
March 31, 2020 | 367.30M |
December 31, 2019 | 451.80M |
September 30, 2019 | 304.40M |
June 30, 2019 | 294.60M |
March 31, 2019 | 291.10M |
December 31, 2018 | 62.30M |
September 30, 2018 | 369.20M |
June 30, 2018 | 364.80M |
March 31, 2018 | 330.80M |
December 31, 2017 | 409.88M |
Date | Value |
---|---|
September 30, 2017 | 306.77M |
June 30, 2017 | 306.91M |
March 31, 2017 | 296.85M |
December 31, 2016 | 325.94M |
September 30, 2016 | 270.04M |
June 30, 2016 | 292.04M |
March 31, 2016 | 289.68M |
December 31, 2015 | 294.95M |
September 30, 2015 | 209.99M |
June 30, 2015 | 174.59M |
March 31, 2015 | 158.99M |
December 31, 2014 | 175.31M |
September 30, 2014 | 144.00M |
June 30, 2014 | 96.73M |
March 31, 2014 | 103.23M |
December 31, 2013 | 99.06M |
September 30, 2013 | 97.61M |
June 30, 2013 | 72.46M |
March 31, 2013 | 77.26M |
December 31, 2012 | 57.74M |
September 30, 2012 | 46.88M |
June 30, 2012 | 47.70M |
March 31, 2012 | 58.43M |
December 31, 2011 | 36.35M |
September 30, 2011 | 32.92M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
294.60M
Minimum
Jun 2019
737.70M
Maximum
Dec 2023
472.05M
Average
450.00M
Median
Mar 2022
SG&A Expense (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 369.10M |
Eli Lilly and Co | 1.463B |
CytomX Therapeutics Inc | 7.827M |
Pfizer Inc | 4.575B |
Puma Biotechnology Inc | 19.82M |